Medical Facilities earnings date
Medical Facilities (31F) Q3 2026 Earnings Report
DE:31F Q3 2026 EPS Results
- Actual EPS
- EUR 0.25
- Consensus EPS
- EUR 0.11
- Beat/Miss
- Beat by +EUR 0.14
- One Year Ago EPS
- EUR 0.21
DE:31F Q3 2026 Revenue Results
- Actual Revenue
- EUR 59.54M
- Expected Revenue
- EUR 56.59M
- Beat/Miss
- Beat by +EUR 2.96M
- YoY Revenue Growth
- -17.42%
Earnings Announcement Details
- Quarter
- Q3 2026
- Date
- 11/12/2026
- Time
- Before Open
- Conference Call
- Thursday, November 12, 2026
Medical Facilities's next earnings date is estimated for March 11, 2027, based on past reporting schedules.
Q3 2026 Earnings Call Audio
Q3 2026 Earnings Slide Deck
No slide deck is available for this earnings event.
Q3 2026 Earnings Call Summary
The call was strongly positive overall. Revenue and profitability grew at notable rates, the company generated strong cash and maintained no corporate-level debt, and it continued returning capital to shareholders. These positives outweighed the reported declines in surgical volume and increases in operating, supply, compensation, and G&A expenses.
The call did not provide specific forward-looking financial guidance, including no guidance for revenue, surgical case volume, operating expenses, income from operations, EBITDA, or capital returns.
- Strong Revenue Growth Driven by Favorable Case and Payer MixThird-quarter revenue increased 9.8% year over year to $65.9 million, driven primarily by the combined impact of case and payer mix, including growth in spine procedures, higher acuity orthopedic cases, pain management cases, and payer rate increases.
- Improved Operating ProfitabilityIncome from operations increased 17.3% to $11.2 million, while EBITDA increased 13.5% to $14.1 million. Management attributed the improvement to the favorable case and payer mix.
- Share Repurchases and Capital ReturnsMFC fully utilized its normal course issuer bid purchase limit of approximately 1.8 million common shares by mid-July. Through the first nine months of the year, the company repurchased just under 1.7 million shares for $21.5 million. Since the change in corporate strategy in Q3 2022, MFC has returned approximately CAD 219.6 million to shareholders through NCIBs, substantial issuer bids, and dividends.
- Strong Cash Position and No Corporate DebtThe company ended the quarter with consolidated cash of $70.8 million, including $60.7 million at the corporate level, and remained free of corporate-level debt. Management stated that the balance sheet provides significant financial flexibility and supports its capital return strategy.
- Higher Net Working CapitalConsolidated net working capital was $67.4 million at quarter end, compared with $54 million at the end of December. Cash and cash equivalents increased to $70.8 million from $43.4 million, primarily due to the sale of Oklahoma Spine Hospital in Q1, partially offset by the removal of OSH's held-for-sale balances and current assets and liabilities.
DE:31F Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Mar 11, 2027 | 2026 (Q4) | 0.32- | 0.14 | ― | ― |
| Nov 12, 2026 | 2026 (Q3) | 0.110.25 | 0.21 | 21.74% (+0.05) | |
| Aug 06, 2026 | 2026 (Q2) | 0.160.08 | 0.18 | -55.00% (-0.10) | |
| May 07, 2026 | 2026 (Q1) | 1.270.19 | 0.15 | 23.53% (+0.04) | |
| Mar 12, 2026 | 2025 (Q4) | 0.320.14 | 0.53 | -74.58% (-0.40) | |
| Nov 06, 2025 | 2025 (Q3) | 0.240.21 | 0.27 | -23.33% (-0.06) | |
| Aug 07, 2025 | 2025 (Q2) | 0.190.18 | -0.02 | 1100.00% (+0.20) | |
| May 08, 2025 | 2025 (Q1) | 0.200.15 | 0.06 | 142.86% (+0.09) | |
| Mar 13, 2025 | 2024 (Q4) | 0.370.53 | 0.35 | 51.28% (+0.18) | |
| Nov 07, 2024 | 2024 (Q3) | 0.450.27 | -0.01 | 3100.00% (+0.28) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
